Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fasiglifam - Takeda

Drug Profile

Fasiglifam - Takeda

Alternative Names: TAK-875

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Benzofurans; Small molecules; Sulfones
  • Mechanism of Action FFAR1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 27 Dec 2013 Discontinued - Phase-III for Type-2 diabetes mellitus (combination therapy) in USA, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Croatia, the Czech Republic, Estonia, France, Germany, Hong Kong, Hungary, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Peru, the Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Thailand, Ukraine and United Kingdom (PO)
  • 27 Dec 2013 Discontinued - Phase-III for Type-2 diabetes mellitus (monotherapy) in Argentina, Bulgaria, Hungary, Guatemala, Mexico, Slovakia, Ukraine and USA (PO)
  • 27 Dec 2013 Discontinued - Phase-III for Type-2 diabetes mellitus in Australia, China, Japan, New Zealand, South Korea and Taiwan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top